Q2 FY26 results: revenue up 11%, H1 turns to loss; buys 2% in Vedang subsidiary

Pat NegativeExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

BLUSPRING · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹77.10

prior close

₹77.09

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-1.0% vs market

Diversified Commercial Services peers, median of 68sector+0.2%-0.8% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.8 pts less than its Diversified Commercial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-1.3

15m

-1.5

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.4-1.0+0.2-0.8

Next day

-3.4+0.0-3.4+0.0-3.4

-0.6-0.2-0.4+0.3-0.9

+2.0+0.7+1.4+0.5+1.6

+2.4+0.6+1.8-0.4+2.8

-0.8+0.5-1.3-0.4-0.4

-2.3+0.3-2.6-2.3-0.0

15d

-5.8-1.5-4.4-1.7-4.2

-15.5-6.6-9.0-6.3-9.2

-15.2-3.2-12.1-6.1-9.1

-25.0-5.2-19.8-13.6-11.5

UpDownMarket · Nifty Microcap 250Sector · Diversified Commercial Services peers, median of 68Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bluspring reported Q2 FY26 consol revenue of Rs 8,574.76 mn, up 11% YoY. Q2 PAT rose to Rs 35.21 mn from Rs 17.85 mn. But H1 FY26 slipped into a consol loss of Rs 36.33 mn vs Rs 17.94 mn profit YoY, hit by Rs 12.71 mn demerger expenses. Standalone H1 PAT surged to Rs 74.57 mn. Board approved buying 2% more in subsidiary Vedang Cellular for Rs 4.16 cr, taking stake to 98.98%.

Likely market impact

Mixed: H1 consol loss of Rs 36.33 mn worries investors despite Q2 PAT recovery and strong standalone performance.